Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof

A method for improving, or treating a lipid metabolism disorder and/or sugar metabolism disorder in a subject in need thereof, comprising administering an effective amount of a lactic acid producing bacterium, a treated product thereof, or a mixture thereof to the subject, thereby improving, or treating the lipid metabolism disorder and/or sugar metabolism disorder in the subject,

• wherein the effective amount corresponds to about 105 cells/gram to about 1014 cells/gram of the lactic acid producing bacterium;
• wherein the lactic acid producing bacterium is Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255), Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), or a mutant or bred strain thereof;
• wherein the lactic acid producing bacterium has dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ, wherein
• (a) the PPARα agonistic activity is about 70% or more of the PPARα agonistic activity of a positive control, as measured by a PPARα reporter assay;
• and
• (b) the PPARγ agonistic activity is about 30% or more of the PPARγ agonistic activity of a positive control, as measured by a PPARγ reporter assay.

A method for reducing subcutaneous fat and/or visceral fat in a subject in need thereof, comprising administering an effective amount of a lactic acid producing bacterium, a treated product thereof, or a mixture thereof to the subject, thereby reducing subcutaneous fat and/or visceral fat in the subject,

• wherein the effective amount corresponds to about 105 cells/gram to about 1014 cells/gram of the lactic acid producing bacterium;
• wherein the lactic acid producing bacterium is Lactobacillus amylovorus CP1563 strain (Accession Number FERM BP-11255), Lactobacillus amylovorus CP1562 strain (Accession Number FERM BP-11379), or a mutant or bred strain thereof;
• wherein the lactic acid producing bacterium has dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ, wherein
• (a) the PPARα agonistic activity is about 70% or more of the PPARα agonistic activity of a positive control, as measured by a PPARα reporter assay;
• and
• (b) the PPARγ agonistic activity is about 30% or more of the PPARγ agonistic activity of a positive control, as measured by a PPARγ reporter assay.